alkeran süstelahuse pulber ja lahusti
aspen pharma trading limited - melfalaan - süstelahuse pulber ja lahusti - 50mg 1tk
alkeran õhukese polümeerikattega tablett
aspen pharma trading limited - melfalaan - õhukese polümeerikattega tablett - 2mg 25tk
enspryng
roche registration gmbh - satralizumab - neuromyelitis optica - immunosupressandid - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.
dapagliflozin viatris
viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - diabeetis kasutatavad ravimid - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.
hemlibra
roche registration limited - emicizumab - hemofiilia a. - antihemorraagilised ained - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra saab kasutada kõigis vanuserühmades.
onpattro
alnylam netherlands b.v. - patisiran naatrium - amüloidoos, perekondlik - muud närvisüsteemi ravimid - onpattro on näidustatud ravi päriliku transthyretin-vahendatud amüloidoos (hattr amüloidoos) täiskasvanud patsientidel, kellel on stage 1 ja stage 2 polüneuropaatia.
orfiril süstelahus
desitin arzneimittel gmbh - valproehape - süstelahus - 100mg 1ml 3ml 5tk
depakine süstelahuse pulber ja lahusti
sanofi-aventis estonia oÜ - valproehape - süstelahuse pulber ja lahusti - 400mg 4tk
depakine chrono 500 mg toimeainet prolongeeritult vabastav tablett
sanofi winthrop industrie - valproehape - toimeainet prolongeeritult vabastav tablett - 500mg 30tk
depakine chrono 300 mg toimeainet prolongeeritult vabastav tablett
sanofi winthrop industrie - valproehape - toimeainet prolongeeritult vabastav tablett - 300mg 100tk